Fortress Biotech, Inc. (FBIOP) EBITDA Margin (2015 - 2026)
Fortress Biotech (FBIOP) posted quarterly EBITDA Margin of 34.07% for Q4 2025, up 12314.0% year-over-year from N/an in Q4 2024, and up 11.8% quarter-over-quarter from 38.63% in Q3 2025.
Fortress Biotech, Inc. (FBIOP) EBITDA Margin (2015 - 2026) Analysis & Trends
Fortress Biotech's EBITDA Margin history runs 11 years deep, the most recent figure standing at 34.07% for Q4 2025.
- In Q4 2025, EBITDA Margin rose 12314.0% year-over-year to 34.07%; the TTM figure through Dec 2025 stood at 117.64% (up 7344.0% YoY), while the FY2025 annual figure was 114.67%, up 7671.0% from the prior year.
- EBITDA Margin for Q4 2025 stood at 34.07%, up from 38.63% in the prior quarter.
- The five-year high for EBITDA Margin was 95.09% in Q4 2022, with the low at 27649.68% in Q2 2021.
- The 5-year median for EBITDA Margin is 248.79% (2025), against an average of 4544.47%.
- The sharpest annual moves came in 2021 and 2022: EBITDA Margin slumped 2738114 bps in 2021, then surged 2737040 bps in 2022.
- Fortress Biotech's EBITDA Margin stood at 106.01% in 2021, then surged by 190 bps to 95.09% in 2022, then tumbled by 235 bps to 128.56% in 2023, then slipped by 22 bps to 157.21% in 2024, then soared by 78 bps to 34.07% in 2025.
- Business Quant data shows FBIOP's EBITDA Margin at 34.07% in Q4 2025, 38.63% in Q3 2025, and 243.01% in Q2 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -53.46% |
| Dec 31, 2025 | -34.07% |
| Sep 30, 2025 | -38.63% |
| Jun 30, 2025 | -243.01% |
| Mar 31, 2025 | -169.85% |
| Dec 31, 2024 | -157.21% |
| Sep 30, 2024 | -151.04% |
| Jun 30, 2024 | -186.55% |
| Mar 31, 2024 | -280.63% |
| Dec 31, 2023 | -128.56% |
| Sep 30, 2023 | -7,559.34% |
| Jun 30, 2023 | -27,379.78% |
| Mar 31, 2023 | -483.90% |
| Dec 31, 2022 | 95.09% |
| Sep 30, 2022 | -13,937.91% |
| Jun 30, 2022 | -279.28% |
| Mar 31, 2022 | -8,192.37% |
| Dec 31, 2021 | -106.01% |
| Sep 30, 2021 | -254.58% |
| Jun 30, 2021 | -27,649.68% |